Pliant Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to PLN-74809 for the treatment of idiopathic pulmonary fibrosis (IPF).
PLN-74809 is a dual selective inhibitor of the αVβ1 and αVβ6 integrins. It modulates these fibrotic tissue-specific integrins, which selectively block activation of TGF-β, preventing the growth of fibrotic tissue within the lung and liver. Targeting TGF-β signaling in a tissue-specific manner allows the drug to modulate the fibrotic cascade with maximum clinical effects while avoiding adverse events; TGF-β is a regulator of physiological healing and pathological fibrosis.
The first-in-human trials are being planned for PLN-74809; IPF currently affects approximately 140,000 people in the US. The drug candidate will also be evaluated in patients with primary sclerosing cholangitis (PSC).
For more information visit PliantRx.com.
This article originally appeared on MPR